Hybrid retroviral vector with MCK enhancers inserted in LTR for stable and specific expression of human factor IX in skeletal muscle

Chinese Medical Journal

Volumn 117, Issue 6, 2004, Pages 893-898

  Wang, Jian Min ^a   Hou, Jun ^b   Qiu, Xin Fang ^a   Kurachi, Kotoku ^c   Xue, Jing Lun ^a  

^a FUDAN UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Gene expression; Human factor IX; Hybrid; Muscle specificity; Retroviral vectors

Indexed keywords

BLOOD CLOTTING FACTOR 9; COMPLEMENTARY DNA; CREATINE KINASE; RETROVIRUS VECTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENHANCER REGION; GENE DELETION; GENE EXPRESSION; GENE INSERTION; GENE SEQUENCE; GENETIC TRANSDUCTION; IN VITRO STUDY; IN VIVO STUDY; INTRON; LONG TERMINAL REPEAT; MALE; MOLECULAR STABILITY; MOUSE; MUSCLE CELL; MYOBLAST; NONHUMAN; SCID MOUSE; SKELETAL MUSCLE; TISSUE SPECIFICITY;

ANIMALS; CREATINE KINASE; CREATINE KINASE, MM FORM; ENHANCER ELEMENTS (GENETICS); FACTOR IX; GENE EXPRESSION; GENETIC TECHNIQUES; GENETIC VECTORS; HYBRIDIZATION, GENETIC; ISOENZYMES; MICE; MICE, SCID; RETROVIRIDAE; TERMINAL REPEAT SEQUENCES;

EID: 3242709521     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Yao SN, Smith KJ, Kurachi K. Primary myoblast-mediatid gene transfer: Persistent expression of human factor IX in mice. Gene Ther 1994;1:99-107.
2. Bohl D, Naffakh N, Heard JM. Long-term control of erythropoietin secretion by doxycycline in mice transplanted with engineered primary myoblasts. Nat Med 1997;3:299-305.
3. Mulligan RC. The basic science of gene therapy. Science 1993;260:926-932.
4. Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs 2000; 60:249-271.
5. Hu WS, Pathak VK. Design of retroviral vectors and helper cells for gene therapy. Pharmacol Rev 2000;52:493-511.
6. Williams DA, Smith FO. Progress in the Use of Gene Transfer Methods to Treat Genetic Blood Diseases. Hum Gene Ther 2000;11:2059-2066.
7. Wang JM, Zheng H, Sugahara Y, et al. Construction of human factor IX expression vectors in retroviral vector frames optimized for muscle cells. Hum Gene Ther 1996;7:1743-1756.
8. Wang JM, Zheng H, Blaivas M, et al. Persistent systemic production of human factor IX in mice by skeletal myoblast-mediated gene transfer: feasibility of repeat application to obtain therapeutic levels. Blood 1997;90:1075-1082.
9. Miller N, Whelan J. Progress in transcriptionally targeted and regulatable vectors for genetic therapy. Hum Gene Ther 1997;8:803-815.
10. Naffakh N, Pinset C, Montarras D, et al. Long-term secretion of therapeutic proteins from genetically modified skeletal muscles. Hum Gene Ther 1996;7:11-21.
11. Ferrari G, Salvatori G, Rossi C, et al. A retroviral vector containing a muscle-specific enhancer drives gene expression only in differentiated muscle fibers. Hum Gene Ther 1995;6: 733-742.
12. Diaz RM, Eisen T, Hart IR, et al. Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma. J Virol 1998;72:789-795.
13. Jager U, Zhao Y, Porter CD. Endothelial cell-specific transcriptional targeting from a hybrid long terminal repeat retrovirus vector containing human prepro-endothelin-1 promoter sequences. J Virol 1999;73:9702-9709.
14. Danno S, Itoh K, Baum C, et al. Efficient gene transfer by hybrid retroviral vectors to murine spermatogenic cells. Hum Gene Ther 1999;10:1819-1831.
15. Wahlfors JJ, Morgan RA. Production of minigene-containing retroviral vectors using an alphavirus/retrovirus hybrid vector system. Hum Gene Ther 1999;10:1197-1206.
16. Kurachi S, Hitomi Y, Furukawa M, et al. Role of intron I in expression of the human factor IX gene. J Biol Chem 1995; 270:5276-5281.
17. Shinnick TM, Lerner RA, Sutcliffe JG. Nucleotide sequence of moloney murine leukaemia virus. Nature 1981;293:543-548.
18. Majors J. Retroviruses, strategies of replication. The structure and function of retroviral long terminal repeats. In: Swanstrom R. Vogt PK, eds. Germany: Springer-Verlag; 1990:49-92.
19. Couture LA, Mullen CA, Morgan RA. Retroviral vectors containing chimeric promoter/enhancer elements exhibit cell-type-specific gene expression. Hum Gene Ther 1994;5:667-677.
20. Miller AD, Bender MA, Harris EA, et al. Design of retrovirus vectors for transfer and expression of the human beta-globin gene. J Virol 1988;62:4337-4435.
21. Jonsson JJ, Habel DE, Mclvor RS. Retrovirus-mediated transduction of an engineered intron-containing purine nucleoside phosphorylase gene. Hum Gene Ther 1995;6:611-623.
22. Sternberg EA, Spizz G, Perry WM, et al. Identification of upstream and intragenic regulatory elements that confer cell-type-restricted and differentiation- specific expression on the muscle creatine kinase gene. Mol Cell Biol 1988;8:2896-2909.
23. Martin KA, Walsh K. Mader SL. The mouse creatine kinase paired E-box element confers muscle-specific expression to a heterologous promoter. Gene 1994;142:275-278.